Effects of fixed combination of indacaterol/glycopyrronium in chronic obstructive pulmonary disease: state-of-the art review
https://doi.org/10.18093/0869-0189-2018-28-2-224-233
Abstract
Long-acting bronchodilators (long-acting β2-agonists (LABA), long-acting anticholinergics (LAMA) and their combinations) are the basic drugs for treatment of stable chronic obstructive pulmonary disease (COPD). Indacaterol/glycopyrronium (IND/GLY) is the first fixed LABA/LAMA combination acquired significant evidence of its efficacy for improvement lung function, symptoms, and quality of life, and decrease in the rate of acute exacerbations of COPD. The aim of this review was to reassess clinical efficacy of IND/GLY in treatment of COPD with regard to recent data and to outline the further role of this combination in therapy of COPD.
About the Authors
S. N. Avdeev
I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University);
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University); Head of Clinical Division, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Doctor of Medicine, Professor, Corresponding Member of Russian Academy of Sciences, Head of Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University); Head of Clinical Division, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
N. V. Trushenko
I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University);
Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia
Russian Federation
Candidate of Medicine, Researcher, Research Center for Monitoring and Control of Respiratory Diseases, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; Assistant Lecturer, Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University)
Russian Federation
Candidate of Medicine, Researcher, Research Center for Monitoring and Control of Respiratory Diseases, Federal Pulmonology Research Institute, Federal Medical and Biological Agency of Russia; Assistant Lecturer, Department of Pulmonology, I.M.Sechenov First Moscow State Medical University, Healthcare Ministry of Russia (Sechenov University)
References
1. Roche N. Stable COPD treatment: where are we? COPD. 2018, Apr. 2: 1–7. DOI: 10.1080/15412555.2018.1445214 [Epub ahead of print].
2. GOLD 2018. Global Strategy for the Diagnosis, Management and Prevention of COPD. Updated 2018. Available at: http://www.goldcopd.org/ [Accessed 16 May, 2018].
3. Rossi A., Aisanov Z., Avdeev S. et al. Mechanisms, assessment and therapeutic implications of lung hyperinflation in COPD. Respir. Med. 2015; 109 (7): 785–802. DOI: 10.1016/j.rmed.2015.03.010.
4. Avdeev S.N. Lung hyperinflation in patients with chronic obstructive pulmonary disease. Pul’monologiya. 2006; (5): 82–96 (in Russian).
5. Donohue J.F., Jones P.W., Bartels C. et al. Corrlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther. 2018; 49: 11–19. DOI: 10.1016/j.pupt.2017.12.005.
6. Cazzola M., Calzetta L., Page C.P. et al. Translational study searching for synergy between glycopyrronium and indacaterol. COPD. 2014; 12 (2): 175–181. DOI: 10.3109/15412555.2014.922172.
7. Ficker J.H., Rabe K.F., Welte T. Role of dual bronchodilators in COPD: a review of the current evidence for indacaterol/glycopyrronium. Pulm. Pharmacol. Ther. 2017; 45: 19–33. DOI: 10.1016/j.pupt.2017.04.002.
8. Van der Molen T., Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim. Care. Respir. J. 2012; 21 (1): 101–108. DOI: 10.4104/pcrj.2011.00102.
9. Mahler D.A., Decramer M., D`Urzo A. et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43 (6): 1599–1609. DOI: 10.1183/09031936.00124013.
10. Deas S.D., Huprikar N. Dual bronchodilatator therapy for chronic obstructive pulmonary disease: evidence for the efficacy and safety of fixed dose combination treatments in the setting of recent guideline updates. Curr. Opin. Pulm. Med. 2018; 24 (2): 130–137. DOI: 10.1097/MCP.0000000000000450.
11. Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 10.1056/NEJMoa1516385.
12. Aisanov Z., Avdeev S., Arkhipov V. et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; (13): 183–187. DOI: 10.2147/COPD.S153770.
13. Aisanov Z.R., Avdeev S.N., Arkhipov V.V. et al. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Pul’monologiya. 2017; 27 (1): 13–20. DOI: 10.18093/0869-0189-2017-27-1-13-20 (in Russian).
14. Avdeev S.N., Trushenko N.V. Dual bronchodilation: a novel paradigm of continued therapy of chronic obstructive pulmonary disease. Prakticheskaya pul’monologiya. 2015; (3): 24–32 (in Russian).
15. Avdeev S.N. A role of fixed combinations of long-acting anticholinergics and long-acting β2-agonists in treatment of chronic obstructive pulmonary disease. Pul’monologiya. 2015; 25 (1): 93–100. DOI: 10.18093/0869-0189-2015-25-1-93-100 (in Russian).
16. Cazzola M., Rogliani P. Comparative effectiveness of indacaterol/glycopyrronium in the treatment of chronic obstructive pulmonary disease. J. Comp. Eff. Res. 2017; 6 (7): 627–636. DOI: 10.2217/cer-2017-0037.
17. Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42 (6): 1484–1494. DOI: 10.1183/09031936.00200212.
18. Mahler D.A., Kerwin E., Ayers T. et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (Indacaterol/Glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015; 192 (9): 1068–1079. DOI: 10.1164/rccm.201505-1048OC.
19. Calzetta L., Rogliani P., Matera M.G., Cazzola M. A systematic review with meta-analysis of dual bronchodilation with LAMA/LABA for the treatment stable COPD. Chest. 2016; 149 (5): 1181–1196. DOI: 10.1016/j.chest.2016.02.646.
20. Vogelmeier C.F., Gaga M., Aalamian-Mattheis M. et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir. Res. 2017; 18 (1): 140. DOI: 10.1186/s12931-017-0622-x.
21. Zhong N., Wang C., Zhou N. et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int. J. Сhron. Obstruct. Pulmon. Dis. 2015; 5 (10): 1015–1026. DOI: 10.2147/COPD.S84436.
22. Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 2013; 1 (1): 51–60. DOI: 10.1016/S2213-2600(12)70052-8.
23. Beeh K.M., Korn S., Beier J. et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir. Med. 2014; 108 (4): 584–592. DOI: 10.1016/j.rmed.2014.01.006.
24. Martinez F.J., Foster G., Curtis J.L. et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am. J. Respir. Crit. Care Med. 2006; 173 (12): 1326–1334. DOI: 10.1164/rccm.200510-1677OC.
25. Barr R.G., Bluemke D.A., Ahmed F.S. et al. Percent emphysema, airflow obstruction and impaired left ventricular filling. N. Engl. J. Med. 2010; 362 (3): 217–227. DOI: 10.1056/NEJMoa0808836.
26. Kawut S.M., Poor H.D., Parikh M.A. et al. Cor pulmonale parvus in chronic obstructive pulmonary disease and emphysema: the MESA COPD study. J. Am. Coll. Cardiol. 2014; 64 (19): 2000–2009. DOI: 10.1016/j.jacc.2014.07.991.
27. Watz H., Waschki B., Meyer T. et al. Decreasing cardiac chamber sizesand associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010; 138 (1): 32–38. DOI: 10.1378/chest.09-2810.
28. Smith B.M., Prince M.R., Hoffman E.A. et al. Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic Study of Atherosclerosis COPD Study. Chest. 2013; 144 (4): 1143–1151. DOI: 10.1378/chest.13-0183.
29. Hohfeld J.M., Vogel-Claussen J., Biller H. et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir. Med. 2018; 6 (5): 368–378. DOI: 10.1016/S2213-2600(18)30054-7.
30. Ferguson G., Barnes N., Mehta R. et al. Cardio- and cerebro-vascular safety profile of QVA149 in patients with COPD: a pooled analysis. Eur. Respir. J. 2013; 42 (Suppl. 57): P4139.
31. Avdeev S.N. A novel fixed combination of long-acting anticholinergic glycopyrronium bromide and long-acting β2-agonist indacaterol: perspectives of therapy for COPD. Meditsinskiy sovet. 2016; (15): 11–16. DOI: 10.21518/2079-701X-2016-15-11-16 (in Russian).
32. Wedzicha J.A., Dahl R., Buhl R. et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir. Med. 2014; 108 (10): 1498–1507. DOI: 10.1016/j.rmed.2014.07.011.
33. Avdeev S.N. Preventive strategies for acute exacerbation of chronic obstructive pulmonary disease. Doktor.ru. 2017; 10 (139): 40–48 (in Russian).
34. Anzueto A.R., Vogelmeier C.F., Kostikas K. et al. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; (12): 1325–1337. DOI: 10.2147/COPD.S133307.
35. Beeh K.M., Burgel P.R., Franssen F.M.E. et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 2017; 196 (2): 139–149. DOI: 10.1164/rccm.201609-1794CI.
36. Bhatt S.P., Soler X., Wang X. et al. Association between functional small airway disease and FEV1 decline in COPD. Am. J. Respir. Crit. Care Med. 2016; 194 (2): 178–84. DOI: 10.1164/rccm.201511-2219OC.
37. Gohy S.T., Detry B.R., Lecocq M. et al. Polymeric immunoglobulin receptor down-regulation in chronic obstructive pulmonary disease. Persistence in the cultured epithelium and role of transforming growth factor-β. Am. J. Respir. Crit. Care Med. 2014; 190 (5): 509–521. DOI: 10.1164/rccm.201311-1971OC.
38. Kistemaker L.E., Oenema T.A., Meurs H., Gosens R. Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci. 2012; 91 (21-22): 1126–1133. DOI: 10.1016/j.lfs.2012.02.021.
39. Haag S., Matthiesen S., Juergens U.R., Racke K. Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur. Respir. J. 2008; 32 (3): 555–562. DOI: 10.1183/09031936.00129307.
40. Wessler I., Kirkpatrick C.J. Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans. Br. J. Pharmacol. 2008; 154 (8): 1558–1571. DOI: 10.1038/bjp.2008.185.
41. Namba Y., Togo S., Tulafu M. et al. Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes. Respir. Res. 2017; 18 (1): 46. DOI: 10.1186/s12931-017-0529-6.
42. Profita M., Bonanno A., Siena L. et al. Smoke, choline acetyltransferase, muscarinic receptors and fibroblast proliferation in chronic obstructive pulmonary disease. J. Pharmacol. Exp. Ther. 2009; 329 (2): 753–63. DOI: 10.1124/jpet.108.145888.
Review
For citations:
Avdeev S.N., Trushenko N.V. Effects of fixed combination of indacaterol/glycopyrronium in chronic obstructive pulmonary disease: state-of-the art review. PULMONOLOGIYA. 2018;28(2):224-233. (In Russ.) https://doi.org/10.18093/0869-0189-2018-28-2-224-233
Views:
839
Email this article 